Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.

Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial<a class="excerpt-read-more" href=" More ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

A personalised cancer vaccine developed by Moderna and Merck shows promise in reducing melanoma metastasis risk by 38% using ...

Moderna cancer vaccine data confirms a 42% cut in melanoma recurrence risk, but an ESMO embargo breach triggered wild swings ...

A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back.

Moderna shares ended Friday’s session modestly lower, extending the sharp losses recorded in the previous trading sessions.

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

UK retail volumes fell 0.4% in September as warm weather curbed autumn purchases; Q3 still rose 0.7%, but rising energy, fuel ...